EADV 2022: Post-Hoc Analysis Shows Roflumilast Effective and Safe by Racial and Ethnic Subgroups in Seborrheic Dermatitis
The highly potent phosphodiesterase-4 inhibitor significantly improved disease severity, erythema, scaling, and itch
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.